CD19 and acute lymphoblastic leukemia: In various studies, it has been reported that patients with R/R ALL indications when treated with CD19-directed CAR-T-cell therapy showed durable response; however, the follow-up data revealed the downregulation of CD19 antigens, along with the development of disease resistance in 30–70% patients who had a recurrent disease post-therapy [58,59].